Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00511134 · ClinicalTrials.gov registry record · Phase 4
Study of Lunesta Versus Placebo for Sleep Problems Related to Smoking Cessation and Zyban
A Phase 4 study, sponsored by Yale University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 4
- Enrollment target
NCT00511134 is a Phase 4 study that was terminated before completion, run by Yale University. The registered enrollment target is 4 participants.
The verdict
NCT00511134, a Phase 4 study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 4 participants
- Enrollment target
Study Summary
Objectives: The primary objective of this study is to determine the efficacy of eszopiclone at treating sleep problems related to withdrawal from nicotine in healthy smokers attempting smoking cessation. Sleep disturbances are a significant problem for smokers who are trying to quit smoking. Smokers may be more likely to have sleep problems and both nicotine withdrawal and agents used to aid smoking cessation (e.g., pharmacotherapies) may disrupt sleep. Lunesta (eszopiclone) is a medication that has been approved by the FDA to treat insomnia. Eszopiclone's efficacy for treating insomnia makes it a promising agent for treating nicotine withdrawal-related symptoms of sleep disturbance. This study will be 7 weeks duration. All participants will begin taking Zyban at the beginning of week 1 and will be asked to try to quit smoking at the beginning of week 2. Participants will also begin to take Lunesta or matched placebo (3 mg qd x 6 weeks) on the target quit date at the beginning of week 2. All subjects will receive eight (8) weekly sessions of brief individual supportive smoking cessation counseling. Hypothesis: It is hypothesized that significantly fewer sleep problems will be reported by participants taking Lunesta as compared to placebo. Specifically, it is expected that participants taking Lunesta will report less difficulty falling and staying asleep, higher sleep quality, and less insomnia-related fatigue and distress than participants taking placebo.
Interventions
- DRUG Eszopiclone
- DRUG Bupropion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2007-04 |
| Est. Completion | 2008-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00511134
The ClinicalTrials.gov registry entry for NCT00511134 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Eszopiclone is the first listed.
NCT00511134 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00511134 about?
NCT00511134 is a clinical study titled "Study of Lunesta Versus Placebo for Sleep Problems Related to Smoking Cessation and Zyban". Objectives: The primary objective of this study is to determine the efficacy of eszopiclone at treating sleep problems related to withdrawal from nicotine in healthy smokers attempting smoking cessation. Sleep disturbances are a significant problem for smokers who are trying to quit smoking. Smoke...
What is the current status of trial NCT00511134?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 4 participants. The study started on 2007-04. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00511134?
The interventions under investigation include: Eszopiclone (DRUG), Bupropion (DRUG).
Who is sponsoring clinical trial NCT00511134?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.